Israel Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Competitiv

According to BioIntel360, diabetes market in Israel is expected to grow by 9.6% on annual basis to reach US$1,331.7 million in 2025.

The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 10.5%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 8.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 1,214.7 million to approximately USD 1,976.1 million.

Key Trends and Drivers in Israel
The Israeli diabetes devices and therapeutics market is being reshaped by increased CGM adoption, integration of digital health for remote monitoring, advancements in therapeutic delivery systems, and updated regulatory frameworks. These trends will intensify over the next 2–4 years, contributing to more efficient patient monitoring, refined treatment protocols, and overall market expansion.

Expand Adoption of Continuous Glucose Monitoring (CGM)
• Israeli healthcare providers are integrating continuous glucose monitoring systems into diabetes management protocols across public hospitals and specialized clinics. Pilot programs in cities like Tel Aviv and Jerusalem have begun incorporating CGM data into routine treatment plans.
• National health insurers' revisions in reimbursement policies and updates in clinical guidelines have supported wider CGM use. In line with global MedTech practices, local clinical research emphasizes the value of real-time data for improving glycemic control.
• CGM adoption is expected to intensify as reimbursement structures mature and supporting clinical evidence grows. Expanded use may lead to more timely treatment adjustments and improved diabetes management outcomes.

Integrate Digital Health Solutions for Remote Monitoring
• Digital platforms that support remote monitoring and telemedicine are being introduced in diabetes care settings throughout Israel. Regional initiatives in areas like Haifa have implemented digital dashboards to centralize patient data and facilitate remote consultations.
• Government-backed digital health strategies and increased investments in healthcare IT are key drivers. Broader shifts in healthcare delivery models and evolving support from insurers are accelerating the integration of digital solutions.
• The adoption of digital health solutions is projected to grow steadily, enhancing communication between patients and providers. Over the medium term, remote monitoring is expected to improve clinical decision-making and overall patient management.

Advanced Therapeutic Delivery Systems
• Connected therapeutic devices, including smart insulin pens and automated insulin pumps, are entering the Israeli market. Recent evaluations in select clinics have focused on these devices to assess their impact on dosing accuracy and treatment adherence.
• Technological progress, supported by local clinical studies, is encouraging the development of connected delivery systems. Increased research investments and gradual modifications in reimbursement policies pave the way for broader adoption.
• The adoption of connected therapeutic devices is expected to increase as clinical practices adjust and reimbursement frameworks evolve. The trend will likely contribute to more precise treatment protocols and enhanced patient management.

Update Regulatory and Reimbursement Frameworks
• Regulatory bodies in Israel are revising approval processes and reimbursement models to better accommodate new diabetes devices and therapies. Recent policy updates from health authorities reflect efforts to streamline market access for conventional and digital solutions.
• Healthcare reform initiatives and cost-containment measures are driving these regulatory adjustments. Recent publications underscore the need for clear reimbursement pathways that support emerging MedTech innovations.
• A more defined regulatory framework is anticipated to boost market confidence and attract further investments in advanced diabetes technologies. These changes are expected to intensify, leading to broader adoption and improved patient access.

Competitive Landscape in Israel
The Israeli diabetes devices and therapeutics market comprises a dynamic mix of established multinational leaders and emerging domestic players. Recent strategic partnerships, mergers, and acquisitions are reshaping competitive dynamics with an increasing focus on digital integration and regulatory alignment. In the coming years, intensified competition and strategic consolidation are expected to drive innovation and enhance patient management across Israel.

Assess Current Market Conditions
• The Israeli market features a blend of multinational corporations and domestic innovators in diabetes care. A structured reimbursement system and defined regulatory pathways create multiple channels for product adoption.

Key Players and New Entrants
• Multinational manufacturers maintain a strong presence through long-term collaborations with major healthcare institutions. These firms offer comprehensive portfolios covering both monitoring devices and therapeutic systems.
• Local startups and technology firms are entering the market with digital health solutions and connected therapeutic devices designed for the local context. Recent market analyses indicate these new entrants leverage pilot programs and strategic partnerships with regional hospitals.

Review Recent Partnerships, Mergers, and Acquisitions
• Recent publications report partnerships between established global players and local innovators to enhance data integration and device connectivity. Mergers and acquisitions during the past 12 months suggest efforts to consolidate technological expertise and expand market offerings.
• These strategic activities lead to a more interconnected market landscape, promoting shared innovation and smoother regulatory compliance. Consolidation trends align product development with the evolving needs of Israel’s healthcare system.

Future Competitive Dynamics (Next 2–4 Years)
• The competitive landscape is expected to evolve with further consolidation as multinational firms expand their digital health offerings and local entrants secure strategic alliances. Industry reports suggest a segmentation between providers of traditional devices and those prioritizing digital innovations.
• Intensified competition is likely to drive product innovation and refine patient management strategies. Over the next 2–4 years, strategic collaborations and market consolidation are expected to reinforce Israel's competitive positioning.

This report provides a detailed data-centric analysis of the diabetes industry in Israel, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.

BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.

Scope

This report provides an in-depth, data-centric analysis of the Israel diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments:

Diabetes Devices and Therapeutics Market Share by Category
• Diagnosis and Monitoring Devices
• Therapeutics

Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
• Blood Glucose Monitoring Devices
• Insulin Delivery Devices
• Diabetes Management and Mobile Applications
• Artificial Pancreas Devices

Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
• Self-Monitoring Blood Glucose Devices
• Continuous Blood Glucose Monitoring Devices
• Test Strips
• Lancets

Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
• Insulin Pumps
• Insulin Pens
• Insulin Syringes

Diabetes Devices and Therapeutics Market Share by Therapeutics
• Oral Anti-Diabetic Drugs
• Insulin
• Non-Insulin Injectable Drugs
• Combination Drugs

Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• SGLT-2 Inhibitors

Diabetes Devices and Therapeutics Market Share by Insulin
• Basal or Long-Acting
• Bolus or Fast-Acting
• Traditional Human Insulin Drugs
• Insulin Biosimilars

Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Amylin Analogue

Diabetes Devices and Therapeutics Market Share by Combination Drugs
• Combination Insulin
• Oral Combination

Diabetes Devices and Therapeutics Market Share by Route of Administration
• Subcutaneous
• Intravenous
• Others

Diabetes Devices and Therapeutics Market Share by Type of Diabetes
• Type 1 Diabetes
• Type 2 Diabetes

Diabetes Devices and Therapeutics Market Share by Distribution Channels
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Diabetes Devices and Therapeutics Market Share by End User
• Hospitals
• Diabetes Clinics
• Homecare

Reasons to Buy

• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user.

• Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly.

• Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation.